HIGH PERFORMANCE ANTIBODIES … AND MORE

Infectious Disease

    Primary Antibodies

  • CD81 Antibody [1.3.3.22]

    Catalog Number: 33-829

    Clonality: Monoclonal

    Tested Applications: Flow, Func, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Mouse

    Conjugate: Unconjugated

    Size: 100 ug

    2 Image(s)

    • IHC testing of FFPE human lymph node with CD81 antibody (clone 1.3.3.22). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.
    • IHC testing of FFPE human tonsil with CD81 antibody (clone 1.3.3.22). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.

  • CX3CR1 Antibody

    Catalog Number: 2093

    Clonality: Polyclonal

    Tested Applications: ELISA, Flow, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    15 Image(s)

    • <strong>Figure 1 Western Blot Validation in Human Cells </strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 KD Validation in 293 Cells</strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 293 cells transfected with control siRNAs. Lane 2: 293 cells transfected with CX3CR1 siRNAs.
    • <strong>Figure 3 Western Blot Validation in THP1 Cells </strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.2 μg/mL Lane 1: 0.5 μg/mL Lane 1: 1 μg/mL
    • <strong>Figure 4 Western Blot Validation in Human Spleen Lysates</strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (1 μg/mL) in the absence (lane 1) or presence of blocking peptide (lane 2), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Western Blot Validation in Rat Spleen Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093, (A; 1 μg/mL, B; 2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 6 Flow Cytometry Validation of CX3CR1 in THP-1 Cells</strong><br> Overlay histogram showing THP-1 cells stained with 2093 (red line, 1μg/1x10<sup>6</sup> cells). 1 h incubation at 4˚C in 2% FBS/PBS. Followed by secondary antibody 488 goat anti-rabbit IgG (H+L) at 1/500 dilution for 1 h 4˚C. <br> <br> Isotype control antibody (Green line) was rabbit IgG1 (1μg/1x10<sup>6</sup> cells) used under the same conditions. Acquisition of >10,000 events was performed.
    • <strong>Figure 7 Immunofluorescence Validation of CX3CR1 In K562 Cells </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling CX3CR1 with 2093 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on K562 cells.
    • <strong>Figure 8 Immunofluorescence Validation of CX3CR1 in Human Heart </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human heart tissue labeling CX3CR1 with 2093 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
    • <strong>Figure 9 Immunofluorescence Validation of CX3CR1 in Mouse Heart Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse heart tissue labeling CX3CR1 with 2093 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 10 Immunohistochemistry Validation of CX3CR1 in Rat Heart Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded rat heart tissue using anti-CX3CR1 antibody (2093) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 11 Immunofluorescence Validation of CX3CR1 in Rat Heart Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed rat heart tissue labeling CX3CR1 with 2093 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 12 Immunofluorescence Validation of CX3CR1 in Human Atherosclerosis (Lucas et al., 2003)</strong><br> CX3CR1-positive cells in coronary artery sections was detected by anti-CX3CR1 antibodies by double staining with an anti–smooth muscle actin antibody (yellow).
    • <strong>Figure 13 Regulated Expression Validation of CX3CR1 in Mouse Bone Marrow-derived NK Cells (Barlic et al., 2003)</strong><br> Western blot analysis of CX3CR1 expression detected by anti-CX3CR1 antibodies was induced by IL-2 but was inhibited by IL-15. Mouse skeletal muscle was for negative control and mouse brain was for positive control.
    • <strong>Figure 14 Flow Cytometry Validation of CX3CR1 in Peripheral Blood Mononuclear Cells (PBMCs) of Patients (Yajima et al., 2005)</strong><br> Flow cytometry analysis of CX3CR1 expression detected by anti-CX3CR1 antibodies. Protein expression was more pronounced on CD4<sup>+</sup> and CD8<sup>+</sup> T cells from patients with untreated active systemic lupus erythematosus (SLE) as compared to those with rheumatoid arthritis (RA) or healthy controls.
    • <strong>Figure 15 CX3CR1 Deficiency Validation in Transgenic Mice (Kumar et al., 2013)</strong><br> Transgenic CX3CR1 gfp (C57BL6/J background) mice, in which either one (CX3CR1 gfp/+ ) or both (CX3CR1 gfp/gfp ) copies of the CX3CR1 gene were interrupted by fluorescent protein (GFP). More CX3CR1 positive cells (green) are found in vascular wall of CX3CR1 gfp/+ mice, but not in CX3CR1 gfp/gfp mice, where cells remained in perivascular region due to leaky microvessels. CX3CR1 expression was detected by anti-CX3CR1 antibodies.

  • CXCR4 Antibody

    Catalog Number: 1009

    Clonality: Polyclonal

    Tested Applications: ELISA, Flow, ICC, IF, IHC-P, IP, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    12 Image(s)

    • <strong>Figure 1 Western Blot Validation of CXCR4 in HeLa Cells </strong><br> Loading: 15 μg of lysates per lane. Antibodies: 1009 (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines</strong><br> Loading: 15 μg of lysates per lane. Antibodies: 1009 (1 μg/mL), 1012 (1 μg/mL), and beta-actin (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 3 Validation with CXCR4 siRNA Knockdown in HeLa Cells</strong><br> HeLa cells were transfected with control siRNAs (lane 1) or CXCR4 siRNAs (lane 2) Loading: 10 μg of HeLa whole cell lysates per lane. Antibodies: 1009 (2 μg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 4 Animal Species Reactivity </strong><br> Loading: Lysates/proteins at 20 μg per lane. Antibodies: 1009 (2 μg/mL) or 1012 (2 μg/mL). 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Recombinant Protein Test </strong><br> Loading: CXCR4 partial recombinant protein (Novus Biologicals, Cat# H00007852-Q01). Lane 1: Anti-CXCR4 antibody (0.1 μg/mL) 1 h incubation at RT in 5% NFDM/TBST. Lane 2: Coomassie blue staining. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 6 Immunofluorescence Validation of CXCR4 in HeLa Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling CXCR4 with 1009 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on HeLa cells.
    • <strong>Figure 7 Flow Cytometry Validation of CXCR4 in HeLa Cells</strong><br> Overlay histogram showing HeLa cells stained with 1009 (red line, 1μg/1x106 cells). 1 h incubation at 4˚C in 2% FBS/PBS. Followed by secondary antibody 488 goat anti-rabbit IgG (H+L) at 1/500 dilution for 1 h 4˚C. <br> <br> Isotype control antibody (Green line) was mouse IgG1 (1μg/1x106 cells) used under the same conditions.
    • <strong>Figure 8 Immunohistochemistry Validation of CXCR4 in Human Spleen</strong><br> Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-CXCR4 antibody (1009) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A Goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 9 Immunocytochemistry Validation of CXCR4 in HeLa Cells </strong><br> Immunocytochemical analysis of HeLa cells using anti-CXCR4 antibody (1009) at 2 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 10 KO Validation of CXCR4 by Flow Cytometry (Ödemis, et al., 2010) </strong><br> Astrocytes from wild-type or CXCR4 knockout mice were stained with primary antibodies against CXCR4 and FITC-labeled secondary antibodies, and subsequently subjected to flow cytometry. CXCR4−/− astrocytes (red) showed loss of CXCR4 cell-surface expression compared with wild-type cells (black).
    • <strong>Figure 11 Overexpression Validation of CXCR4 (Kozak et al., 2002) </strong><br> U87MG and U87MG-CXCR4 extracts were included as negative and positive controls, respectively, for CXCR4 detection with anti-CXCR4 antibodies.
    • <strong>Figure 12 WB Validation of CXCR4 in Human Metastatic Melanoma (Scala et al., 2006) </strong><br> CXCR4 protein was detected in the human metastatic melanoma cell lines and human melanoma cell line (colo38), but not in the human primary melanocytes (MPR1) with anti-CXCR4 antibodies.
3 Item(s)
per page
Shop By
Currently Shopping by:
  1. Remove This Item Conjugate: Unconjugated
  2. Remove This Item Tested Applications: Func
  3. Remove This Item Tested Applications: Flow
  4. Remove This Item Species Reactivity: Rat
  5. Remove This Item Species Reactivity: HIV-1
  6. Remove This Item Species Reactivity: MRSA
Clear All
Refine by
Product type
  1. Primary Antibodies (3)
Conjugate
  1. Unconjugated (3)
Host Species
  1. Mouse (1)
  2. Rabbit (2)
Modifications
  1. None (3)
Tested Applications
  1. ELISA (29)
  2. Flow (3)
  3. Func (1)
  4. ICC (4)
  5. IF (20)
  6. IHC (1)
  7. IHC-P (17)
  8. IP (1)
  9. WB (31)
Show Less Show More
Species Reactivity
  1. HIV-1 (0)
  2. Human (8)
  3. Mouse (3)
  4. MRSA (0)
  5. Rat (3)
  6. Virus (7)
Show Less Show More
Clonality
  1. Monoclonal (1)
  2. Polyclonal (2)

Research Area

Custom Antibody Services

Product Type

Support

About ProSci

Resources

Contact ProSci

  • 12170 Flint Place
    Poway, CA 92064, USA
  •  
  • Toll-Free: +1 (888) 513 9525
  • Phone: +1 (858) 513 2638
  • Fax: +1 (858) 513 2692
  • Email: info@prosci-inc.com

Follow Us:

  • ProSci Facebook
  • ProSci Twitter
  • ProSci LinkedIn

  • ProSci Newsletter
  • ProSci Research Gate